by Sam Eskandari | Oct 11, 2018 | News
October 11, 2018, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its CEO Dr. Lui Franciosi and Medical Director Dr. Scott Alexander will be attending the 3rd International...
by Sam Eskandari | Oct 10, 2018 | News
VANCOUVER, British Columbia, Oct. 10, 2018 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Cannevert Therapeutics Ltd.’s (“Cannevert”) Director of Regulatory Affairs and Quality Assurance,...
by Sam Eskandari | Oct 5, 2018 | News
VANCOUVER, B.C., Oct. 05, 2018 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce along with the Institute for Medical Cannabis (the “IMC”) of Puerto Rico, the signing of a Memorandum of...
by Sam Eskandari | Sep 28, 2018 | News
September 28, 2018, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Agrima Botanicals Corp (“Agrima”) where both...
by Sam Eskandari | Sep 27, 2018 | News
September 20, 2018, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce a non-brokered private placement offering of 13,157,900 at $0.19 per Unit raising up to $2,500,000 with no share...
by Sam Eskandari | Sep 19, 2018 | News
VANCOUVER, British Columbia, Sept. 19, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to provide a corporate update on its activities, milestones over the first three quarters of...
